Leading Canadian transfer pricing cases favour domestic rules over OECD guidelines

Until the decision in the GlaxoSmithKline (Glaxo) case, all previous Canadian court decisions had slavishly applied the OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations. How do the guidelines now fit into the law and a practical strategy of establishing the correct transfer prices?

Locked content

The article you are trying to view is only available to subscribers and current trialists